Features - VJNeurology

Highlights from ECTRIMS 2022

In this feature, we spotlight hot topics in MS discussed at ECTRIMS, from the inclusion of optic nerve lesions in…

MR CLEAN-LATE results presented at the World Stroke Congress 2022

The MR CLEAN-LATE prospective, randomized study of over 500 patients with acute ischemic stroke showed that endovascular thrombectomy (EVT) provides…

AMX0035 receives FDA approval for ALS

On September 29, 2022, the Food and Drug Administration (FDA) approved AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS),…

Intravenous thrombolysis in patients with ischemic stroke and DOAC intake

Current guidelines warn against the use of intravenous thrombolysis in patients with ischemic stroke and recent direct oral anticoagulant (DOAC)…

Updates on direct oral anticoagulants and hemorrhagic stroke

A wealth of research continues to investigate anticoagulation-associated intracranial hemorrhage and the optimal strategies for prevention and management…

AMT-130: the first gene therapy on the horizon for Huntington’s disease?

The first interim data has been published from a Phase I/II trial testing the safety and tolerability of AMT-130. If…

BTK inhibitors: From the treatment of cancer to multiple sclerosis

The role of BTK inhibitors (BTKis) in cancer treatment has been well-established, but what prospects do they have in treating…

FDA approval of ravulizumab for myasthenia gravis

Myasthenia gravis (MG) is a rare disorder, exhibiting the archetypic traits of both the neuromuscular junction and autoantibody-mediated disease –…